Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AFXS | ISIN: US2210151005 | Ticker-Symbol: C17
Tradegate
02.06.25 | 21:32
3,490 Euro
+6,40 % +0,210
1-Jahres-Chart
CORVUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CORVUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,3203,39511:01
3,3303,41010:00

Aktuelle News zur CORVUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis105Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3...
► Artikel lesen
CORVUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiCorvus Pharmaceuticals, Inc. - 8-K, Current Report2
20.05.Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating4
09.05.Why Is Corvus Pharmaceuticals Stock Soaring On Friday?4
09.05.Corvus Pharmaceuticals shares surge on positive trial results1
09.05.Corvus Pharmaceuticals-Aktien steigen nach positiven Studienergebnissen2
09.05.Pre-market Movers: ZK International, Jade Biosciences, Twin Vee Powercats, Corvus Pharmaceuticals, Iovance Biotherapeutics851OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green ZK International Group Co., Ltd. (ZKIN) is up over...
► Artikel lesen
09.05.Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected3
08.05.Corvus Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
08.05.Corvus Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
08.05.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results89Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts...
► Artikel lesen
23.04.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 20251
09.04.Corvus Pharmaceuticals, Inc. - 8-K, Current Report3
09.04.Corvus Pharmaceuticals expands board with new director1
09.04.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors1
27.03.Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript1
26.03.Corvus Pharmaceuticals outlines clinical milestones for soquelitinib in 20253
25.03.Corvus Pharmaceuticals, Inc. - 10-K, Annual Report1
25.03.Corvus Pharmaceuticals GAAP EPS of -$0.18 misses by $0.061
25.03.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results153Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and...
► Artikel lesen
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2